Literature DB >> 18094159

Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement.

Caroline Ruat1, Catherine Caillet, Alexandre Bidaut, James Simon, Albert D M E Osterhaus.   

Abstract

We investigated the ability of adjuvanted, inactivated split-virion influenza A virus (H5N1) vaccines to protect against infection and demonstrated that the disease exacerbation phenomenon seen with adjuvanted formaldehyde-inactivated respiratory syncytial virus and measles virus investigational vaccines did not occur with these H5N1 vaccines. Macaques were vaccinated twice with or without an aluminum hydroxide or oil-in-water emulsion adjuvanted vaccine. Three months later, animals were challenged with homologous wild-type H5N1. No signs of vaccine-induced disease exacerbation were seen. With either adjuvant, vaccination induced functional and cross-reactive antibodies and protected the lungs and upper respiratory tract. Without an adjuvant, the vaccine provided partial protection. Best results were obtained with the emulsion adjuvant.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18094159      PMCID: PMC2258952          DOI: 10.1128/JVI.01928-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  13 in total

1.  Pathogenesis of influenza A (H5N1) virus infection in a primate model.

Authors:  G F Rimmelzwaan; T Kuiken; G van Amerongen; T M Bestebroer; R A Fouchier; A D Osterhaus
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.

Authors:  Elena A Govorkova; Richard J Webby; Jennifer Humberd; Jon P Seiler; Robert G Webster
Journal:  J Infect Dis       Date:  2006-06-09       Impact factor: 5.226

3.  Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets.

Authors:  Aleksandr S Lipatov; Erich Hoffmann; Rachelle Salomon; Hui-Ling Yen; Robert G Webster
Journal:  J Infect Dis       Date:  2006-09-12       Impact factor: 5.226

4.  Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection.

Authors:  Rik L De Swart; Thijs Kuiken; Helga H Timmerman; Geert van Amerongen; Bernadette G Van Den Hoogen; Helma W Vos; Herman J Neijens; Arno C Andeweg; Albert D M E Osterhaus
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

Authors:  T Rowe; R A Abernathy; J Hu-Primmer; W W Thompson; X Lu; W Lim; K Fukuda; N J Cox; J M Katz
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

6.  Immunopathogenesis of vaccine-enhanced RSV disease.

Authors:  P J Openshaw; F J Culley; W Olszewska
Journal:  Vaccine       Date:  2001-10-15       Impact factor: 3.641

7.  Viral replication and development of specific immunity in macaques after infection with different measles virus strains.

Authors:  R S van Binnendijk; R W van der Heijden; G van Amerongen; F G UytdeHaag; A D Osterhaus
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

8.  Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis).

Authors:  T Kuiken; G F Rimmelzwaan; G Van Amerongen; A D M E Osterhaus
Journal:  Vet Pathol       Date:  2003-05       Impact factor: 2.221

Review 9.  H5N1 viruses and vaccines.

Authors:  Kanta Subbarao; Catherine Luke
Journal:  PLoS Pathog       Date:  2007-03       Impact factor: 6.823

10.  Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.

Authors:  Menno D de Jong; Cameron P Simmons; Tran Tan Thanh; Vo Minh Hien; Gavin J D Smith; Tran Nguyen Bich Chau; Dang Minh Hoang; Nguyen Van Vinh Chau; Truong Huu Khanh; Vo Cong Dong; Phan Tu Qui; Bach Van Cam; Do Quang Ha; Yi Guan; J S Malik Peiris; Nguyen Tran Chinh; Tran Tinh Hien; Jeremy Farrar
Journal:  Nat Med       Date:  2006-09-10       Impact factor: 53.440

View more
  21 in total

1.  CD154 expression is associated with neutralizing antibody titer levels postinfluenza vaccination in stem cell transplant patients and healthy adults.

Authors:  Aprille Seidel; David Smith; Edward Yung; Lia Aquino; Tumul Srivastava; Vinod Pullarkat; Ricardo Spielberger; Stephen J Forman; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-08       Impact factor: 5.742

Review 2.  H5N1 vaccines in humans.

Authors:  Mariana Baz; Catherine J Luke; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  Virus Res       Date:  2013-05-28       Impact factor: 3.303

3.  Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model.

Authors:  Shin Murakami; Ayaka Iwasa; Kiyoko Iwatsuki-Horimoto; Mutsumi Ito; Maki Kiso; Hiroshi Kida; Ayato Takada; Chairul A Nidom; Le Quynh Mai; Shinya Yamada; Hirotaka Imai; Yuko Sakai-Tagawa; Yoshihiro Kawaoka; Taisuke Horimoto
Journal:  Vaccine       Date:  2008-09-17       Impact factor: 3.641

4.  Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity.

Authors:  Jae-Min Song; Chi-Won Choi; Sang-Oh Kwon; Richard W Compans; Sang-Moo Kang; Seung Il Kim
Journal:  J Proteome Res       Date:  2011-07-08       Impact factor: 4.466

Review 5.  H5N1 pathogenesis studies in mammalian models.

Authors:  Jessica A Belser; Terrence M Tumpey
Journal:  Virus Res       Date:  2013-02-28       Impact factor: 3.303

6.  Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.

Authors:  Dominick J Laddy; Jian Yan; Amir S Khan; Hanne Andersen; Amanda Cohn; Jack Greenhouse; Mark Lewis; Jody Manischewitz; Lisa R King; Hana Golding; Ruxandra Draghia-Akli; David B Weiner
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

7.  Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates.

Authors:  Shufang Fan; Yuwei Gao; Kyoko Shinya; Chris Kafai Li; Yanbing Li; Jianzhong Shi; Yongping Jiang; Yongbing Suo; Tiegang Tong; Gongxun Zhong; Jiasheng Song; Ying Zhang; Guobin Tian; Yuntao Guan; Xiao-Ning Xu; Zhigao Bu; Yoshihiro Kawaoka; Hualan Chen
Journal:  PLoS Pathog       Date:  2009-05-01       Impact factor: 6.823

8.  Induction of long-term protective immune responses by influenza H5N1 virus-like particles.

Authors:  Sang-Moo Kang; Dae-Goon Yoo; Aleksandr S Lipatov; Jae-Min Song; C Todd Davis; Fu-Shi Quan; Li-Mei Chen; Ruben O Donis; Richard W Compans
Journal:  PLoS One       Date:  2009-03-02       Impact factor: 3.240

Review 9.  Animal models for the study of influenza pathogenesis and therapy.

Authors:  Dale L Barnard
Journal:  Antiviral Res       Date:  2009-01-25       Impact factor: 5.970

10.  MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.

Authors:  Joost H C M Kreijtz; Yasemin Suezer; Gerrie de Mutsert; Geert van Amerongen; Astrid Schwantes; Judith M A van den Brand; Ron A M Fouchier; Johannes Löwer; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.